Quinolone, everninomycin, glycylcyline, carbapenem, lipopeptide and cephem antibacterials in clinical development

被引：32

作者：

Bronson, JJ ^{[1
]}

Barrett, JF ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Infect Dis Microbiol Discovery & Early Dev, Wallingford, CT 06492 USA

来源：

CURRENT MEDICINAL CHEMISTRY | 2001年 / 8卷 / 14期

关键词：

D O I：

10.2174/0929867013371653

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The development of antibacterials was a very successful endeavor in the pharmaceutical company repertoire through the late 1970s, when interest in investing in antibiotic research and development temporarily waned. More recently, there have been a number of failures in late stage development or post-launch of human antibiotics. The answer to the dilemma of less-than-desired success may be the introduction of novel classes of agents, as well as development of new agents in traditional classes. This review provides an overview of the various "miscellaneous" antibacterials in development, excluding glycopeptides, macrolides, ketolides, and oxazolidinones. Among the agents highlighted in this review are the clinical candidates of quinolones, everninomycins, carbapenems, lipopeptides, glycylcyclines, and cephems. In several cases, certain quinolone agents described in this review will have been approved for marketing before press time.

引用

页码：1775 / 1793

页数：19

共 167 条

[31] FUCHS PC, 1998, 38 ICAAC
[32] Primary targets of fluoroquinolones in Streptococcus pneumoniae
Fukuda, H
Hiramatsu, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) : 410 - 412
[33] Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice
Fukuoka, T
Kawada, H
Kitayama, A
Koga, T
Kubota, M
Harasaki, T
Kamai, Y
Ohya, S
Yasuda, H
Iwata, M
Kuwahara, S
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) : 23 - 27
[34] In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem
Fukuoka, T
Ohya, S
Utsui, Y
Domon, H
Takenouchi, T
Koga, T
Masuda, N
Kawada, H
Kakuta, M
Kubota, M
Ishii, C
Ishii, C
Sakagawa, E
Harasaki, T
Hirasawa, A
Abe, T
Yasuda, H
Iwata, M
Kuwahara, S
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) : 2652 - 2663
[35] FUNGTOME J, 1999, 39 ICAAC
[36] FURUHATA K, 1999, 39 ICAAC
[37] GALES AC, 1999, 39 ICAAC
[38] Chemical modifications and structure activity studies of ziracin and related everninomicin antibiotics
Ganguly, AK
McCormick, JL
Saksena, AK
Das, PR
Chan, TM
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (08) : 1209 - 1214
[39] CHEMICAL MODIFICATION OF EVERNINOMICINS
GANGULY, AK
GIRIJAVALLABHAN, VM
MILLER, GH
SARRE, OZ
[J]. JOURNAL OF ANTIBIOTICS, 1982, 35 (05) : 561 - 570
[40] In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345)
Gill, CJ
Jackson, JJ
Gerckens, LS
Pelak, BA
Thompson, RK
Sundelof, JG
Kropp, H
Rosen, H
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) : 1996 - 2001

← 1 2 3 4 5 6 7 8 9 10 →